FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:2271-2281 May 31, 2007 Number 22 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited efficacy and tolerability. Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease.

Methods In this multicenter, phase 3 trial, we randomly assigned 626 patients with previously untreated, poor-prognosis metastatic renal-cell carcinoma to receive 25 mg of intravenous temsirolimus weekly, 3 million U of interferon alfa (with an increase to 18 million U) subcutaneously three times weekly, or combination therapy with 15 mg of temsirolimus weekly plus 6 million U of interferon alfa three times weekly. The primary end point was overall survival in comparisons of the temsirolimus group and the combination-therapy group with the interferon group.

Results Patients who received temsirolimus alone had longer overall survival (hazard ratio for death, 0.73; 95% confidence interval [CI], 0.58 to 0.92; P=0.008) and progression-free survival (P<0.001) than did patients who received interferon alone. Overall survival in the combination-therapy group did not differ significantly from that in the interferon group (hazard ratio, 0.96; 95% CI, 0.76 to 1.20; P=0.70). Median overall survival times in the interferon group, the temsirolimus group, and the combination-therapy group were 7.3, 10.9, and 8.4 months, respectively. Rash, peripheral edema, hyperglycemia, and hyperlipidemia were more common in the temsirolimus group, whereas asthenia was more common in the interferon group. There were fewer patients with serious adverse events in the temsirolimus group than in the interferon group (P=0.02).

Conclusions As compared with interferon alfa, temsirolimus improved overall survival among patients with metastatic renal-cell carcinoma and a poor prognosis. The addition of temsirolimus to interferon did not improve survival. (ClinicalTrials.gov number, NCT00065468 [ClinicalTrials.gov] .)

Source Information

From the Fox Chase Cancer Center, Philadelphia (G.H.); Sidney Kimmel Comprehensive Cancer Center, Baltimore (M.C.); Klinika Onkologii, Oddzial Chemioterapii, Pozna, Poland (P.T.); Our Lady of Mercy Medical Center, Bronx, NY (J.D.); University of California, Los Angeles, Los Angeles (R.F.); McMaster University, Hamilton, ON, Canada (A.K.); Lublin Oncological Center, Lublin, Poland (E.S.); Vanderbilt University Medical Center, Nashville (J.S.); Beth Israel Deaconess Medical Center, Boston (D.M.); National Institute of Oncology, Budapest, Hungary (I.B.); Military Medical Academy, Belgrade, Serbia (Z.K.); Regional Clinical Center of Urology and Nephrology, Kharkov, Ukraine (V.L.); University of Bonn, Bonn, Germany (I.G.H.S.-W.); Kemerovo State Medical Academy, Regional Clinical Hospital, Kemerovo, Russia (O.B.); Ege University Medical Faculty, Izmir, Turkey (E.G.); Wyeth Research, Cambridge, MA (T.O., S.L., L.M.); and Memorial Sloan-Kettering Cancer Center, New York (R.J.M.).

Address reprint requests to Dr. Hudes at the Department of Medical Oncology, Rm. 307, Fox Chase Cancer Center, 333 Cottman Ave., Philadelphia, PA 19111, or at gary.hudes{at}fccc.edu.

Full Text of this Article

Related Letters:

Temsirolimus for Advanced Renal-Cell Carcinoma
Fazio N., Dettori M., Lorizzo K., Ferretti G., Hudes G.
Extract | Full Text | PDF  
N Engl J Med 2007; 357:1050-1051, Sep 6, 2007. Correspondence

This article has been cited by other articles:

• Booth, C. M., Ohorodnyk, P., Eisenhauer, E. A. (2009). Call for Clarity in the Reporting of Benefit Associated With Anticancer Therapies. JCO 27: e213-e214 [Full Text]  
• Dorff, T. B., Goldkorn, A., Quinn, D. I. (2009). Review: Targeted therapy in renal cancer. Therapeutic Advances in Medical Oncology 1: 183-205 [Abstract]  
• Shinohara, N., Kumagai, A., Kanagawa, K., Maruyama, S., Abe, T., Sazawa, A., Nonomura, K. (2009). Multicenter Phase II Trial of Combination Therapy with Meloxicam, a COX-2 Inhibitor, and Natural Interferon-{alpha} for Metastatic Renal Cell Carcinoma. Jpn J Clin Oncol 39: 720-726 [Abstract] [Full Text]  
• Gupta, M., Ansell, S. M., Novak, A. J., Kumar, S., Kaufmann, S. H., Witzig, T. E. (2009). Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood 114: 2926-2935 [Abstract] [Full Text]  
• Rini, B. I., Wilding, G., Hudes, G., Stadler, W. M., Kim, S., Tarazi, J., Rosbrook, B., Trask, P. C., Wood, L., Dutcher, J. P. (2009). Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma. JCO 27: 4462-4468 [Abstract] [Full Text]  
• Ellard, S. L., Clemons, M., Gelmon, K. A., Norris, B., Kennecke, H., Chia, S., Pritchard, K., Eisen, A., Vandenberg, T., Taylor, M., Sauerbrei, E., Mishaeli, M., Huntsman, D., Walsh, W., Olivo, M., McIntosh, L., Seymour, L. (2009). Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163. JCO 27: 4536-4541 [Abstract] [Full Text]  
• Cersosimo, R. J. (2009). Renal cell carcinoma with an emphasis on drug therapy of advanced disease, part 2. Am J Health Syst Pharm 66: 1625-1633 [Abstract] [Full Text]  
• Jonasch, E., Wood, C. G., Matin, S. F., Tu, S.-M., Pagliaro, L. C., Corn, P. G., Aparicio, A., Tamboli, P., Millikan, R. E., Wang, X., Araujo, J. C., Arap, W., Tannir, N. (2009). Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients With Metastatic Renal Cell Carcinoma. JCO 27: 4076-4081 [Abstract] [Full Text]  
• Fung, A. S., Wu, L., Tannock, I. F. (2009). Concurrent and Sequential Administration of Chemotherapy and the Mammalian Target of Rapamycin Inhibitor Temsirolimus in Human Cancer Cells and Xenografts. Clin. Cancer Res. 15: 5389-5395 [Abstract] [Full Text]  
• Hess, G., Herbrecht, R., Romaguera, J., Verhoef, G., Crump, M., Gisselbrecht, C., Laurell, A., Offner, F., Strahs, A., Berkenblit, A., Hanushevsky, O., Clancy, J., Hewes, B., Moore, L., Coiffier, B. (2009). Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma. JCO 27: 3822-3829 [Abstract] [Full Text]  
• Stadler, W. M. (2009). Effective Therapy for Metastatic Renal Cancer, Whither to Now. JCO 27: 3573-3574 [Full Text]  
• El-Salem, M., Raghunath, P. N., Marzec, M., Liu, X., Kasprzycka, M., Robertson, E., Wasik, M. A. (2009). Activation of mTORC1 Signaling Pathway in AIDS-Related Lymphomas. Am. J. Pathol. 175: 817-824 [Abstract] [Full Text]  
• Motzer, R. J., Molina, A. M. (2009). Targeting Renal Cell Carcinoma. JCO 27: 3274-3276 [Full Text]  
• Shackelford, D. B., Vasquez, D. S., Corbeil, J., Wu, S., Leblanc, M., Wu, C.-L., Vera, D. R., Shaw, R. J. (2009). mTOR and HIF-1{alpha}-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc. Natl. Acad. Sci. USA 106: 11137-11142 [Abstract] [Full Text]  
• Larkin, J. M.G., Kipps, E. L.S., Powell, C. J., Swanton, C. (2009). Review: Systemic therapy for advanced renal cell carcinoma. Therapeutic Advances in Medical Oncology 1: 15-27 [Abstract]  
• Rini, B. I. (2009). Metastatic Renal Cell Carcinoma: Many Treatment Options, One Patient. JCO 27: 3225-3234 [Abstract] [Full Text]  
• Ma, W. W., Jacene, H., Song, D., Vilardell, F., Messersmith, W. A., Laheru, D., Wahl, R., Endres, C., Jimeno, A., Pomper, M. G., Hidalgo, M. (2009). [18F]Fluorodeoxyglucose Positron Emission Tomography Correlates With Akt Pathway Activity but Is Not Predictive of Clinical Outcome During mTOR Inhibitor Therapy. JCO 27: 2697-2704 [Abstract] [Full Text]  
• Yuen, J. S.P., Akkaya, E., Wang, Y., Takiguchi, M., Peak, S., Sullivan, M., Protheroe, A. S., Macaulay, V. M. (2009). Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer. Molecular Cancer Therapeutics 8: 1448-1459 [Abstract] [Full Text]  
• Singhal, S. S., Singhal, J., Yadav, S., Sahu, M., Awasthi, Y. C., Awasthi, S. (2009). RLIP76: A Target for Kidney Cancer Therapy. Cancer Res. 69: 4244-4251 [Abstract] [Full Text]  
• Meric-Bernstam, F., Gonzalez-Angulo, A. M. (2009). Targeting the mTOR Signaling Network for Cancer Therapy. JCO 27: 2278-2287 [Abstract] [Full Text]  
• Sternberg, C. N. (2009). Expanding the boundaries of clinical practice: building on experience with targeted therapies. Ann Oncol 20: i1-i6 [Abstract] [Full Text]  
• Ravaud, A. (2009). How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents. Ann Oncol 20: i7-i12 [Abstract] [Full Text]  
• Escudier, B., Kataja, V., On behalf of the ESMO Guidelines Working Group, (2009). Renal cell carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 20: iv81-iv82 [Full Text]  
• Guertin, D. A., Sabatini, D. M. (2009). The Pharmacology of mTOR Inhibition. Sci Signal 2: pe24-pe24 [Abstract] [Full Text]  
• Domhan, S., Zeier, M., Abdollahi, A. (2009). Immunosuppressive therapy and post-transplant malignancy. Nephrol Dial Transplant 24: 1097-1103 [Full Text]  
• Barros Costa, R. L. (2009). Review Article: Targeted Therapy: Comprehensive Review. AM J HOSP PALLIAT CARE 26: 137-146 [Abstract]  
• Klatte, T., Seligson, D. B., LaRochelle, J., Shuch, B., Said, J. W., Riggs, S. B., Zomorodian, N., Kabbinavar, F. F., Pantuck, A. J., Belldegrun, A. S. (2009). Molecular Signatures of Localized Clear Cell Renal Cell Carcinoma to Predict Disease-Free Survival after Nephrectomy. Cancer Epidemiol. Biomarkers Prev. 18: 894-900 [Abstract] [Full Text]  
• Ma, W. W., Adjei, A. A. (2009). Novel Agents on the Horizon for Cancer Therapy. CA Cancer J Clin 59: 111-137 [Abstract] [Full Text]  
• Geissler, E K, Schlitt, H J (2009). Immunosuppression for liver transplantation. Gut 58: 452-463 [Abstract] [Full Text]  
• Hartford, C. M., Desai, A. A., Janisch, L., Karrison, T., Rivera, V. M., Berk, L., Loewy, J. W., Kindler, H., Stadler, W. M., Knowles, H. L., Bedrosian, C., Ratain, M. J. (2009). A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies. Clin. Cancer Res. 15: 1428-1434 [Abstract] [Full Text]  
• Kim, J., Jonasch, E., Alexander, A., Short, J. D., Cai, S., Wen, S., Tsavachidou, D., Tamboli, P., Czerniak, B. A., Do, K. A., Wu, K. J., Marlow, L. A., Wood, C. G., Copland, J. A., Walker, C. L. (2009). Cytoplasmic Sequestration of p27 via AKT Phosphorylation in Renal Cell Carcinoma. Clin. Cancer Res. 15: 81-90 [Abstract] [Full Text]  
• Brugarolas, J. (2009). Molecular Pathways and Targeted Therapies for Renal Cell Carcinoma. Am Soc Clin Oncol Ed Book 2009: 710-715 [Abstract] [Full Text]  
• Biswas, S., Kelly, J., Eisen, T. (2009). Cytoreductive Nephrectomy in Metastatic Clear-Cell Renal Cell Carcinoma: Perspectives in the Tyrosine Kinase Inhibitor Era. The Oncologist 14: 52-59 [Abstract] [Full Text]  
• Amornphimoltham, P., Leelahavanichkul, K., Molinolo, A., Patel, V., Gutkind, J. S. (2008). Inhibition of Mammalian Target of Rapamycin by Rapamycin Causes the Regression of Carcinogen-Induced Skin Tumor Lesions. Clin. Cancer Res. 14: 8094-8101 [Abstract] [Full Text]  
• Brugarolas, J. (2008). In Reply. JCO 26: 5653-5654 [Full Text]  
• Weichhart, T, Saemann, M D (2008). The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications. Ann Rheum Dis 67: iii70-iii74 [Abstract] [Full Text]  
• Ng, C. S., Wood, C. G., Silverman, P. M., Tannir, N. M., Tamboli, P., Sandler, C. M. (2008). Renal Cell Carcinoma: Diagnosis, Staging, and Surveillance. Am. J. Roentgenol. 191: 1220-1232 [Abstract] [Full Text]  
• Ackler, S., Xiao, Y., Mitten, M. J., Foster, K., Oleksijew, A., Refici, M., Schlessinger, S., Wang, B., Chemburkar, S. R., Bauch, J., Tse, C., Frost, D. J., Fesik, S. W., Rosenberg, S. H., Elmore, S. W., Shoemaker, A. R. (2008). ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Molecular Cancer Therapeutics 7: 3265-3274 [Abstract] [Full Text]  
• Stein, W. D., Yang, J., Bates, S. E., Fojo, T. (2008). Bevacizumab Reduces the Growth Rate Constants of Renal Carcinomas: A Novel Algorithm Suggests Early Discontinuation of Bevacizumab Resulted in a Lack of Survival Advantage. The Oncologist 13: 1055-1062 [Abstract] [Full Text]  
• Hutson, T. E., Figlin, R. A., Kuhn, J. G., Motzer, R. J. (2008). Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies. The Oncologist 13: 1084-1096 [Abstract] [Full Text]  
• Neklesa, T. K., Davis, R. W. (2008). Superoxide anions regulate TORC1 and its ability to bind Fpr1:rapamycin complex. Proc. Natl. Acad. Sci. USA 105: 15166-15171 [Abstract] [Full Text]  
• Wang, X., Yue, P., Kim, Y. A., Fu, H., Khuri, F. R., Sun, S.-Y. (2008). Enhancing Mammalian Target of Rapamycin (mTOR)-Targeted Cancer Therapy by Preventing mTOR/Raptor Inhibition-Initiated, mTOR/Rictor-Independent Akt Activation. Cancer Res. 68: 7409-7418 [Abstract] [Full Text]  
• Jiang, Z., Chu, P. G., Woda, B. A., Liu, Q., Balaji, K.C., Rock, K. L., Wu, C.-L. (2008). Combination of Quantitative IMP3 and Tumor Stage: A New System to Predict Metastasis for Patients with Localized Renal Cell Carcinomas. Clin. Cancer Res. 14: 5579-5584 [Abstract] [Full Text]  
• Crispen, P. L., Sheinin, Y., Roth, T. J., Lohse, C. M., Kuntz, S. M., Frigola, X., Thompson, R. H., Boorjian, S. A., Dong, H., Leibovich, B. C., Blute, M. L., Kwon, E. D. (2008). Tumor Cell and Tumor Vasculature Expression of B7-H3 Predict Survival in Clear Cell Renal Cell Carcinoma. Clin. Cancer Res. 14: 5150-5157 [Abstract] [Full Text]  
• Bellmunt, J., Szczylik, C., Feingold, J., Strahs, A., Berkenblit, A. (2008). Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 19: 1387-1392 [Abstract] [Full Text]  
• Negrier, S. (2008). Temsirolimus in metastatic renal cell carcinoma. Ann Oncol 19: 1369-1370 [Full Text]  
• Boone, J, Kate, F J W T., Offerhaus, G J A, van Diest, P J, Rinkes, I H M B., van Hillegersberg, R (2008). mTOR in squamous cell carcinoma of the oesophagus: a potential target for molecular therapy?. J. Clin. Pathol. 61: 909-913 [Abstract] [Full Text]  
• Woodard, J., Sassano, A., Hay, N., Platanias, L. C. (2008). Statin-Dependent Suppression of the Akt/Mammalian Target of Rapamycin Signaling Cascade and Programmed Cell Death 4 Up-Regulation in Renal Cell Carcinoma. Clin. Cancer Res. 14: 4640-4649 [Abstract] [Full Text]  
• Brugarolas, J., Lotan, Y., Watumull, L., Kabbani, W. (2008). Sirolimus in Metatastic Renal Cell Carcinoma. JCO 26: 3457-3460 [Full Text]  
• Trotta, F., Apolone, G., Garattini, S., Tafuri, G. (2008). Stopping a trial early in oncology: for patients or for industry?. Ann Oncol 19: 1347-1353 [Abstract] [Full Text]  
• Signoretti, S., Bratslavsky, G., Waldman, F. M., Reuter, V. E., Haaga, J., Merino, M., Thomas, G. V., Pins, M. R., Libermann, T., Gillespie, J., Tomaszewski, J. E., Compton, C. C., Hruszkewycz, A., Linehan, W. M., Atkins, M. B. (2008). Tissue-Based Research in Kidney Cancer: Current Challenges and Future Directions. Clin. Cancer Res. 14: 3699-3705 [Abstract] [Full Text]  
• Yang, L., Clarke, M. J., Carlson, B. L., Mladek, A. C., Schroeder, M. A., Decker, P., Wu, W., Kitange, G. J., Grogan, P. T., Goble, J. M., Uhm, J., Galanis, E., Giannini, C., Lane, H. A., James, C. D., Sarkaria, J. N. (2008). PTEN Loss Does Not Predict for Response to RAD001 (Everolimus) in a Glioblastoma Orthotopic Xenograft Test Panel. Clin. Cancer Res. 14: 3993-4001 [Abstract] [Full Text]  
• Garcia, J. A., Danielpour, D. (2008). Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Molecular Cancer Therapeutics 7: 1347-1354 [Abstract] [Full Text]  
• Wei, L. H., Su, H., Hildebrandt, I. J., Phelps, M. E., Czernin, J., Weber, W. A. (2008). Changes in Tumor Metabolism as Readout for Mammalian Target of Rapamycin Kinase Inhibition by Rapamycin in Glioblastoma. Clin. Cancer Res. 14: 3416-3426 [Abstract] [Full Text]  
• Verheul, H. M.W., Salumbides, B., Van Erp, K., Hammers, H., Qian, D. Z., Sanni, T., Atadja, P., Pili, R. (2008). Combination Strategy Targeting the Hypoxia Inducible Factor-1{alpha} with Mammalian Target of Rapamycin and Histone Deacetylase Inhibitors. Clin. Cancer Res. 14: 3589-3597 [Abstract] [Full Text]  
• Michaelson, M. D., Iliopoulos, O., McDermott, D. F., McGovern, F. J., Harisinghani, M. G., Oliva, E. (2008). Case 17-2008 -- A 63-Year-Old Man with Metastatic Renal-Cell Carcinoma. NEJM 358: 2389-2396 [Full Text]  
• Llovet, J. M., Di Bisceglie, A. M., Bruix, J., Kramer, B. S., Lencioni, R., Zhu, A. X., Sherman, M., Schwartz, M., Lotze, M., Talwalkar, J., Gores, G. J., for the Panel of Experts in HCC-Design Clinical Tr, (2008). Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma. JNCI J Natl Cancer Inst 100: 698-711 [Abstract] [Full Text]  
• Bukowski, R. M. (2008). How I Treat Renal Cell Carcinoma. J Oncol Pract 4: 150-152 [Full Text]  
• Frei, B. L., Soefje, S. A. (2008). A Review of the Cardiovascular Effects of Oncology Agents. Journal of Pharmacy Practice 21: 146-158 [Abstract]  
• O'Donnell, A., Faivre, S., Burris, H. A. III, Rea, D., Papadimitrakopoulou, V., Shand, N., Lane, H. A., Hazell, K., Zoellner, U., Kovarik, J. M., Brock, C., Jones, S., Raymond, E., Judson, I. (2008). Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors. JCO 26: 1588-1595 [Abstract] [Full Text]  
• Fraenkel, M., Ketzinel-Gilad, M., Ariav, Y., Pappo, O., Karaca, M., Castel, J., Berthault, M.-F., Magnan, C., Cerasi, E., Kaiser, N., Leibowitz, G. (2008). mTOR Inhibition by Rapamycin Prevents {beta}-Cell Adaptation to Hyperglycemia and Exacerbates the Metabolic State in Type 2 Diabetes. Diabetes 57: 945-957 [Abstract] [Full Text]  
• Waxman, J., Kenny, L., Ngan, S. (2008). New treatments for kidney cancer. BMJ 336: 681-682 [Full Text]  
• Moreno, A., Akcakanat, A., Munsell, M. F, Soni, A., Yao, J. C, Meric-Bernstam, F. (2008). Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 15: 257-266 [Abstract] [Full Text]  
• Rini, B. I. (2008). Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin. Clin. Cancer Res. 14: 1286-1290 [Full Text]  
• Fojo, T. (2008). Commentary: Novel Therapies for Cancer: Why Dirty Might Be Better. The Oncologist 13: 277-283 [Full Text]  
• Gridelli, C., Maione, P., Rossi, A. (2008). The Potential Role of mTOR Inhibitors in Non-Small Cell Lung Cancer. The Oncologist 13: 139-147 [Abstract] [Full Text]  
• Booth, C. M., Tannock, I. (2008). Reflections on Medical Oncology: 25 Years of Clinical Trials Where Have We Come and Where Are We Going?. JCO 26: 6-8 [Full Text]  
• Rathmell, W. K., Stadler, W. M., Rini, B. I. (2008). Rational Therapeutic Choices and Strategies for Patients with Metastatic Renal Cancer. Am Soc Clin Oncol Ed Book 2008: 192-198 [Abstract] [Full Text]  
• Costa, L. J., Drabkin, H. A. (2007). Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies. The Oncologist 12: 1404-1415 [Abstract] [Full Text]  
• Ebbinghaus, S., Hussain, M., Tannir, N., Gordon, M., Desai, A. A., Knight, R. A., Humerickhouse, R. A., Qian, J., Gordon, G. B., Figlin, R. (2007). Phase 2 Study of ABT-510 in Patients with Previously Untreated Advanced Renal Cell Carcinoma. Clin. Cancer Res. 13: 6689-6695 [Abstract] [Full Text]  
• Harrison, M. L., Obermueller, E., Maisey, N. R., Hoare, S., Edmonds, K., Li, N. F., Chao, D., Hall, K., Lee, C., Timotheadou, E., Charles, K., Ahern, R., King, D. M., Eisen, T., Corringham, R., DeWitte, M., Balkwill, F., Gore, M. (2007). Tumor Necrosis Factor {alpha} As a New Target for Renal Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and High Dose. JCO 25: 4542-4549 [Abstract] [Full Text]  
• Kwak, E. L., Clark, J. W., Chabner, B. (2007). Targeted Agents: The Rules of Combination. Clin. Cancer Res. 13: 5232-5237 [Abstract] [Full Text]  
• Fazio, N., Dettori, M., Lorizzo, K., Ferretti, G., Hudes, G. (2007). Temsirolimus for Advanced Renal-Cell Carcinoma. NEJM 357: 1050-1051 [Full Text]  
• Ryan, C. W., Goldman, B. H., Lara, P. N. Jr, Mack, P. C., Beer, T. M., Tangen, C. M., Lemmon, D., Pan, C.-X., Drabkin, H. A., Crawford, E. D. (2007). Sorafenib With Interferon Alfa-2b As First-Line Treatment of Advanced Renal Carcinoma: A Phase II Study of the Southwest Oncology Group. JCO 25: 3296-3301 [Abstract] [Full Text]  
• (2007). Survival Benefit from mTOR Inhibition in Advanced Kidney Cancer. JWatch Oncology and Hematology 2007: 1-1 [Full Text]